Malaysian Genomics Pivots to Biopharmaceuticals for Growth
Group reports lower revenue for 2Q on switch to immunotherapy and cell therapies from vaccines
March 7, 2023
by PharmaSources
EdiGene and Neukio enter collaboration to develop next-generation immune cell therapies
EdiGene, Inc and Neukio Biotherapeutics have announced an R&D collaboration to develop next-generation immune cell therapies, Neukio Biotherapeutics informed via a statement.
February 14, 2022
by ExpressPharma
Twist Bioscience, Artisan Development Labs partner to discover cell therapies
Twist Bioscience has teamed up with Artisan Development Labs to discover new antibodies against five undisclosed targets.
January 26, 2022
by pharmaceutical-business-review.
CARsgen Therapeutics Appoints President of U.S. Ops
Richard Daly brings 30 years of pharmaceutical industry experience, including leadership positions in multi-national corporations and biotech companies.
January 17, 2022
by contractpharma
SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience
SQZ Biotechnologies today announced the appointments of Bernard Coulie, M.D., Ph.D., and Patrick Vink, M.D., to its board of directors, adding global commercial and clinical development expertise.
July 2, 2021
by firstwordpharma
Kite and Shoreline Biosciences enter partnership to develop novel allogeneic cell therapies
Kite, a Gilead Company and Shoreline Biosciences announced a strategic partnership to develop novel cell therapies across a variety of cancer targets.
June 18, 2021
by expresspharma
Fujifilm Cellular Dynamics and Lonza Enter Cell Therapy Partnership
Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Lonza Walkersville, Inc., a leading global GMP iPSC manufacturer, have entered into a partnership.
November 17, 2020
by contractpharma
Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of T-Cells
GERMANTOWN, MD – July 14, 2020 – Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs).
August 12, 2020
by PharmaSources.com
Innovent Biologics enters drug development deal with Roche
Chinese biopharmaceutical firm Innovent Biologics has entered a strategic research and development partnership with Roche for various cell therapies and bispecific antibodies.
June 10, 2020
by pharmaceutical-technology